In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Purpose. The treatment of cancer-induced anemia with erythropoietin-stimulating agents (ESAs) is reviewed. Summary. Before the introduction of ESAs, the only treatment option for cancer-related ...

Compared to placebo, high-dose recombinant human erythropoietin within 2 days of life does not improve neurodevelopmental outcomes for preterm infants.

Erythropoietin (EPO), originally discovered as a cytokine that primarily acts on the erythroid progenitor cells in the bone marrow, has recently been recognized to play a crucial role in the nervous ...

Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk ...

Erythropoietin stimulating agents and/or luspatercept showed positive clinical efficacy and safety in patients with VEXAS ...

Are your kidneys working fine? Here are the top 7 signs of healthy kidneys and renal health that your should look out for!

The World Anti-Doping Agency (WADA) is pleased to share positive insights from a study it recently published examining the ...

The Racing Medication and Testing Consortium granted interim accreditation to the University of Kentucky Equine Analytical ...

The document is part of the strategy to use data in a way that more informed decisions are made in various areas of activity ...